Bacteriology and Inflammation in Bronchiectasis
Launched by GUANGZHOU INSTITUTE OF RESPIRATORY DISEASE · Jan 3, 2013
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
Bronchiectasis is a chronic disease arises from progressive airway inflammation and infection. Pro-inflammatory mediators, the products of activated neutrophils recruited to the inflamed sites, are released in bronchiectatic airways and mediate cascades of neutrophil infiltration. This suggests that bacterial infection plays a pivotal role in the neutrophil-derived inflammation leading to the vicious cycle that perpetuates the development of airway destruction and might result in acute exacerbation. Treatments targeting at bacterial infection is therefore necessary, particularly for those w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients of either sex and age between 18 and 70 years
- Exclusion Criteria:
- • Patient judged to have poor compliance
- • Female patient who is lactating or pregnant
- • Patients having concomitant severe systemic illnesses (i.e. coronary heart disease, cerebral stroke, uncontrolled hypertension, active gastric ulcer, malignant tumor, hepatic dysfunction, renal dysfunction)
- • Miscellaneous conditions that would potentially influence efficacy assessment, as judged by the investigators
- • Participation in another clinical trial within the preceding 3 months
About Guangzhou Institute Of Respiratory Disease
The Guangzhou Institute of Respiratory Disease is a leading research institution dedicated to advancing the understanding and treatment of respiratory diseases. With a strong focus on clinical trials, the Institute aims to develop innovative therapeutic strategies and improve patient outcomes through rigorous scientific inquiry. Committed to excellence in respiratory health, it collaborates with national and international partners to conduct cutting-edge research, fostering an environment of collaboration and knowledge exchange. The Institute plays a pivotal role in shaping respiratory medicine through its dedication to high-quality clinical research, training, and public health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Nan-shan Zhong, M. D.
Principal Investigator
Sate Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College
Rong-chang Chen, M. D.
Principal Investigator
Sate Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials